Brown Brothers Harriman & Co. Sells 353 Shares of DexCom, Inc. (NASDAQ:DXCM)

Brown Brothers Harriman & Co. decreased its stake in DexCom, Inc. (NASDAQ:DXCM) by 8.2% in the 3rd quarter, Holdings Channel.com reports. The fund owned 3,930 shares of the medical device company’s stock after selling 353 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in DexCom were worth $263,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of DXCM. Migdal Insurance & Financial Holdings Ltd. bought a new position in DexCom during the second quarter worth about $25,000. Sachetta LLC grew its holdings in DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the period. Riverview Trust Co grew its holdings in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after purchasing an additional 232 shares during the period. DT Investment Partners LLC grew its holdings in DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after purchasing an additional 315 shares during the period. Finally, ORG Partners LLC grew its holdings in DexCom by 1,992.0% during the second quarter. ORG Partners LLC now owns 523 shares of the medical device company’s stock worth $59,000 after purchasing an additional 498 shares during the period. Institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In related news, COO Jacob Steven Leach sold 746 shares of the business’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Sadie Stern sold 4,259 shares of the business’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares in the company, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,431 shares of company stock valued at $399,319. 0.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on DXCM shares. JPMorgan Chase & Co. lifted their price target on DexCom from $75.00 to $85.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Royal Bank of Canada cut their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Oppenheimer cut their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Piper Sandler restated an “overweight” rating and set a $90.00 price objective on shares of DexCom in a research report on Monday, August 26th. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $104.59.

DexCom Stock Performance

NASDAQ DXCM opened at $78.10 on Thursday. The firm’s fifty day moving average price is $71.11 and its two-hundred day moving average price is $88.51. The stock has a market cap of $30.51 billion, a PE ratio of 46.77, a PEG ratio of 2.38 and a beta of 1.17. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.